Assessment Of Safety Of UK-390,957

Pfizer

Status and phase: Completed; Phase 3; Phase 2

Conditions: Ejaculation

Treatments: Drug: UK-390,957

Study type: Interventional

Funder types: Industry

Identifiers

NCT00219609

A3871028

Details and patient eligibility

About

To determine whether UK-390,957 is a safe treatment for premature ejaculation.

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion criteria

• No drug related serious adverse events

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)